1rd4

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:1rd4.jpg|left|200px]]
+
{{Seed}}
 +
[[Image:1rd4.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_1rd4| PDB=1rd4 | SCENE= }}
{{STRUCTURE_1rd4| PDB=1rd4 | SCENE= }}
-
'''An allosteric inhibitor of LFA-1 bound to its I-domain'''
+
===An allosteric inhibitor of LFA-1 bound to its I-domain===
-
==Overview==
+
<!--
-
LFA-1 (lymphocyte function-associated antigen-1) plays a role in intercellular adhesion and lymphocyte trafficking and activation and is an attractive anti-inflammatory drug target. The alpha-subunit of LFA-1, in common with several other integrins, has an N-terminally inserted domain (I-domain) of approximately 200 amino acids that plays a central role in regulating ligand binding to LFA-1. An additional region, termed the I-domain allosteric site (IDAS), has been identified exclusively within the LFA-1 I-domain and shown to regulate the function of this protein. The IDAS is occupied by small molecule LFA-1 inhibitors when cocrystallized or analyzed by (15)N-(1)H HSQC (heteronuclear single-quantum coherence) NMR (nuclear magnetic resonance) titration experiments. We report here a novel arylthio inhibitor that binds the I-domain with a K(d) of 18.3 nM as determined by isothermal titration calorimetry (ITC). This value is in close agreement with the IC(50) (10.9 nM) derived from a biochemical competition assay (DELFIA) that measures the level of inhibition of binding of whole LFA-1 to its ligand, ICAM-1. Having established the strong affinity of the arylthio inhibitor for the isolated I-domain, we have used a range of techniques to further characterize the binding, including ITC, NMR, and X-ray crystallography. We have first developed an effective ITC binding assay for use with low-solubility inhibitors that avoids the need for ELISA-based assays. In addition, we utilized a fast NMR-based assay for the generation of I-domain-inhibitor models. This is based around the collection of HCCH-TOCSY spectra of LFA-1 in the bound form and the identification of a subset of side chain methyl groups that give chemical shift changes upon binding of LFA-1 inhibitors. This subset was used in two-dimensional (13)C-(15)N and (15)N-filtered and -edited two-dimensional NMR experiments to identify a minimal set of intraligand and ligand-protein NOEs, respectively (nuclear Overhauser enhancements). Models from the NMR data were assessed by comparison to an X-ray crystallographic structure of the complex, confirming that the method correctly predicted the essential features of the bound ligand.
+
The line below this paragraph, {{ABSTRACT_PUBMED_14992576}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 14992576 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_14992576}}
==About this Structure==
==About this Structure==
Line 34: Line 38:
[[Category: Taylor, R J.]]
[[Category: Taylor, R J.]]
[[Category: Immune system]]
[[Category: Immune system]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May 3 07:20:59 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 07:00:06 2008''

Revision as of 04:00, 28 July 2008

Image:1rd4.png

Template:STRUCTURE 1rd4

An allosteric inhibitor of LFA-1 bound to its I-domain

Template:ABSTRACT PUBMED 14992576

About this Structure

1RD4 is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.

Reference

Structure of an allosteric inhibitor of LFA-1 bound to the I-domain studied by crystallography, NMR, and calorimetry., Crump MP, Ceska TA, Spyracopoulos L, Henry A, Archibald SC, Alexander R, Taylor RJ, Findlow SC, O'Connell J, Robinson MK, Shock A, Biochemistry. 2004 Mar 9;43(9):2394-404. PMID:14992576

Page seeded by OCA on Mon Jul 28 07:00:06 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/1rd4"
Personal tools